自体树突状细胞和细胞因子诱导的杀伤细胞胸腔灌注联合热疗治疗化疗耐药的肺癌胸腔积液的临床研究

The clinical study of the treatment for the patients with chemotherapy-resistant lung cancer malig- nant pleural effusion by auto DC-CIK cells combined hyperthermia

目的探讨树突状细胞（DC）和细胞因子诱导的杀伤细胞（CIK）胸腔内灌注联合热疗治疗化疗耐药的肺癌胸腔积液的疗效。方法23例化疗耐药的肺癌胸腔积液患者行胸腔置管引流术，待积液引流完毕，胸腔灌注自体DC．CIK细胞，DC—CIK细胞数为（2—3）×10^9／次，30min后，给予患侧胸腔局部热疗60—90min，每天1次，连续灌注3d。结果治疗后患者的临床获益率为69．6％（16／23），不良反应多为自限性，1例患者出现乙肝病毒再激活。结论DC—CIK细胞胸腔灌注联合热疗治疗化疗耐药的肺癌胸腔积液安全有效，不良反应小。

Objective To evaluate the efficacy of the treatment for the patients with chemotherapy- resistant lung cancer malignant pleural effusion by auto DC-CIK cells combined hyperthermia. Methods A total of twenty-three patients were treated with PICC implementation and thoracic infusion DC-CIK cells therapy. The DC-CIK cells were transfused at （2-3） x 109 per dosage and hyperthermia for about 60-90 minutes,once per day for 3 consecutive days. Results The clinical benefit rate of patients was 69. 6% （16/23）. The side effects were self-restricted. HBV （hepatitis B virus） reactivation appeared in one case. Conclusions The intracavitary administration of auto DC-CIK combined hyperthermia is an effective, safe and tolerant way to treat patients with chemotherapy-resistant lung cancer malignant pleural effusion.